Insider filing · MBX

Carl L Gordon bought $12.0M of MBX Biosciences (MBX)

Executed Sep 16 2024, disclosed Sep 17 2024, 1 day later.

Over the 21 trading sessions from the disclosed entry session (Sep 17 2024), the stock returned +9.6% (delay-adjusted); from the execution session (Sep 16 2024), -1.9%. Derived: entry at the session's open, exit at the close 20 sessions later.

CG Carl L Gordon Director profile →

Carl L Gordon (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in BlossomHill Therapeutics, Inc. Common Stock (BLSM). Across 2 priced purchase filings, the average 21-session return was +56.2% from execution and +52.9% from disclosure (delay-adjusted; derived). The largest single filing was $15.0M of SCTX (1,000,000 sh × $15.00, as filed), executed Jul 27.

MBX MBX MBX · 8 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→